The development of fluconazole resistance in Candida albicans – an example of microevolution of a fungal pathogen

Journal of Microbiology

Volumn 54, Issue 3, 2016, Pages 192-201

  Morschhäuser, Joachim ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

drug resistance; fitness costs; gain of function mutation; genome alterations; loss of heterozygosity

Indexed keywords

ANTIFUNGAL AGENT; FLUCONAZOLE;

ANIMAL; ANTIFUNGAL RESISTANCE; CANDIDA ALBICANS; CANDIDIASIS; DRUG EFFECTS; GENETICS; HUMAN; MICROBIOLOGY; MOLECULAR EVOLUTION; PATHOGENICITY;

ANIMALS; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; EVOLUTION, MOLECULAR; FLUCONAZOLE; HUMANS;

EID: 84959195571     PISSN: 12258873     EISSN: 19763794     Source Type: Journal    
DOI: 10.1007/s12275-016-5628-4     Document Type: Review

References (79)

1. Alarco, A.M. and Raymond, M. 1999. The bZip transcription factor Cap1p is involved in multidrug resistance and oxidative stress response in Candida albicans. J. Bacteriol.181, 700–708.
2. Alby, K. and Bennett, R.J. 2009. Stress-induced phenotypic switching in Candida albicans. Mol. Biol. Cell.20, 3178–3191.
3. Andes, D., Forrest, A., Lepak, A., Nett, J., Marchillo, K., and Lincoln, L. 2006. Impact of antimicrobial dosing regimen on evolution of drug resistance in vivo: fluconazole and Candida albicans. Antimicrob. Agents Chemother.50, 2374–2383.
4. Angiolella, L., Stringaro, A.R., De Bernardis, F., Posteraro, B., Bonito, M., Toccacieli, L., Torosantucci, A., Colone, M., Sanguinetti, M., Cassone, A., et al. 2008. Increase of virulence and its phenotypic traits in drug-resistant strains of Candida albicans. Antimicrob. Agents Chemother.52, 927–936.
5. Asai, K., Tsuchimori, N., Okonogi, K., Perfect, J.R., Gotoh, O., and Yoshida, Y. 1999. Formation of azole-resistant Candida albicans by mutation of sterol 14-demethylase P450. Antimicrob. Agents Chemother.43, 1163–1169.
6. Berman, J. and Hadany, L. 2012. Does stress induce (para)sex? Implications for Candida albicans evolution. Trends Genet.28, 197–203.
7. Calvet, H.M., Yeaman, M.R., and Filler, S.G. 1997. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob. Agents Chemother.41, 535–539.
8. 5,6-desaturase attenuates virulence in Candida albicans. Antimicrob. Agents Chemother.49, 3646–3651.
9. Coste, A., Selmecki, A., Forche, A., Diogo, D., Bougnoux, M.E., d’Enfert, C., Berman, J., and Sanglard, D. 2007. Genotypic evolution of azole resistance mechanisms in sequential Candida albicans isolates. Eukaryot. Cell6, 1889–1904.
10. Coste, A., Turner, V., Ischer, F., Morschhäuser, J., Forche, A., Selmecki, A., Berman, J., Bille, J., and Sanglard, D. 2006. A mutation in Tac1p, a transcription factor regulating CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate antifungal resistance in Candida albicans. Genetics172, 2139–2156.
11. Coste, A.T., Crittin, J., Bauser, C., Rohde, B., and Sanglard, D. 2009. Functional analysis of cis- and trans-acting elements of the Candida albicans CDR2 promoter with a novel promoter reporter system. Eukaryot. Cell8, 1250–1267.
12. Coste, A.T., Karababa, M., Ischer, F., Bille, J., and Sanglard, D. 2004. TAC1, transcriptional activator of CDR genes, is a new transcription factor involved in the regulation of Candida albicans ABC transporters CDR1 and CDR2. Eukaryot. Cell3, 1639–1652.
13. Cruz, M.C., Goldstein, A.L., Blankenship, J.R., Del Poeta, M., Davis, D., Cardenas, M.E., Perfect, J.R., McCusker, J.H., and Heitman, J. 2002. Calcineurin is essential for survival during membrane stress in Candida albicans. EMBO J.21, 546–559.
14. Dunkel, N., Blaβ, J., Rogers, P.D., and Morschhäuser, J. 2008a. Mutations in the multi-drug resistance regulator MRR1, followed by loss of heterozygosity, are the main cause of MDR1 overexpression in fluconazole-resistant Candida albicans strains. Mol. Microbiol.69, 827–840.
15. Dunkel, N., Liu, T.T., Barker, K.S., Homayouni, R., Morschhäuser, J., and Rogers, P.D. 2008b. A gain-of-function mutation in the transcription factor Upc2p causes upregulation of ergosterol biosynthesis genes and increased fluconazole resistance in a clinical Candida albicans isolate. Eukaryot. Cell7, 1180–1190.
16. Favre, B., Didmon, M., and Ryder, N.S. 1999. Multiple amino acid substitutions in lanosterol 14a-demethylase contribute to azole resistance in Candida albicans. Microbiology145, 2715–2725.
17. Flowers, S.A., Barker, K.S., Berkow, E.L., Toner, G., Chadwick, S.G., Gygax, S.E., Morschhäuser, J., and Rogers, P.D. 2012. Gain-offunction mutations in UPC2 are a frequent cause of ERG11 upregulation in azole-resistant clinical isolates of Candida albicans. Eukaryot. Cell11, 1289–1299.
18. Flowers, S.A., Colon, B., Whaley, S.G., Schuler, M.A., and Rogers, P.D. 2015. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans. Antimicrob. Agents Chemother.59, 450–460.
19. Forche, A., Abbey, D., Pisithkul, T., Weinzierl, M.A., Ringstrom, T., Bruck, D., Petersen, K., and Berman, J. 2011. Stress alters rates and types of loss of heterozygosity in Candida albicans. mBio2, e00129–11.
20. Forche, A., Alby, K., Schaefer, D., Johnson, A.D., Berman, J., and Bennett, R.J. 2008. The parasexual cycle in Candida albicans provides an alternative pathway to meiosis for the formation of recombinant strains. PLoS Biol.6, e110.
21. Ford, C.B., Funt, J.M., Abbey, D., Issi, L., Guiducci, C., Martinez, D.A., Delorey, T., Li, B.Y., White, T.C., Cuomo, C., et al. 2015. The evolution of drug resistance in clinical isolates of Candida albicans. Elife4, e00662.
22. Franz, R., Kelly, S.L., Lamb, D.C., Kelly, D.E., Ruhnke, M., and Morschhäuser, J. 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob. Agents Chemother.42, 3065–3072.
23. Franz, R., Ruhnke, M., and Morschhäuser, J. 1999. Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses42, 453–458.
24. Harrison, B.D., Hashemi, J., Bibi, M., Pulver, R., Bavli, D., Nahmias, Y., Wellington, M., Sapiro, G., and Berman, J. 2014. A tetraploid intermediate precedes aneuploid formation in yeasts exposed to fluconazole. PLoS Biol.12, e1001815.
25. Hayama, K., Ishibashi, H., Ishijima, S.A., Niimi, K., Tansho, S., Ono, Y., Monk, B.C., Holmes, A.R., Harding, D.R., Cannon, R.D., et al. 2012. A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model. FEMS Microbiol. Lett.328, 130–137.
26. Heilmann, C.J., Schneider, S., Barker, K.S., Rogers, P.D., and Morschhäuser, J. 2010. An A643T mutation in the transcription factor Upc2p causes constitutive ERG11 upregulation and increased fluconazole resistance in Candida albicans. Antimicrob. Agents Chemother.54, 353–359.
27. Hoot, S.J., Smith, A.R., Brown, R.P., and White, T.C. 2011. An A643V amino acid substitution in Upc2p contributes to azole resistance in well-characterized clinical isolates of Candida albicans. Antimicrob. Agents Chemother.55, 940–942.
28. Huang, G., Srikantha, T., Sahni, N., Yi, S., and Soll, D.R. 2009. CO2 regulates white-to-opaque switching in Candida albicans. Curr. Biol.19, 330–334.
29. Huang, G., Yi, S., Sahni, N., Daniels, K.J., Srikantha, T., and Soll, D.R. 2010. N-acetylglucosamine induces white to opaque switching, a mating prerequisite in Candida albicans. PLoS Pathog.6, e1000806.
30. Huang, M., McClellan, M., Berman, J., and Kao, K.C. 2011. Evolutionary dynamics of Candida albicans during in vitro evolution. Eukaryot. Cell10, 1413–1421.
31. Jain, P., Akula, I., and Edlind, T. 2003. Cyclic AMP signaling pathway modulates susceptibility of Candida species and Saccharomyces cerevisiae to antifungal azoles and other sterol biosynthesis inhibitors. Antimicrob. Agents Chemother.47, 3195–3201.
32. Kakeya, H., Miyazaki, Y., Miyazaki, H., Nyswaner, K., Grimberg, B., and Bennett, J.E. 2000. Genetic analysis of azole resistance in the Darlington strain of Candida albicans. Antimicrob. Agents Chemother.44, 2985–2990.
33. Kelly, S.L., Lamb, D.C., and Kelly, D.E. 1999a. Y132H substitution in Candida albicans sterol 14a-demethylase confers fluconazole resistance by preventing binding to haem. FEMS Microbiol. Lett.180, 171–175.
34. 5,6-desaturation. FEBS Lett.400, 80–82.
35. Kelly, S.L., Lamb, D.C., Loeffler, J., Einsele, H., and Kelly, D.E. 1999b. The G464S amino acid substitution in Candida albicans sterol 14a-demethylase causes fluconazole resistance in the clinic through reduced affinity. Biochem. Biophys. Res. Commun.262, 174–179.
36. Kusch, H., Biswas, K., Schwanfelder, S., Engelmann, S., Rogers, P.D., Hecker, M., and Morschhäuser, J. 2004. A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol. Genet. Genomics271, 554–565.
37. Lamb, D.C., Kelly, D.E., White, T.C., and Kelly, S.L. 2000. The R467K amino acid substitution in Candida albicans sterol 14a- demethylase causes drug resistance through reduced affinity. Antimicrob. Agents Chemother.44, 63–67.
38. Lohberger, A., Coste, A.T., and Sanglard, D. 2014. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence. Eukaryot. Cell13, 127–142.
39. MacPherson, S., Akache, B., Weber, S., De Deken, X., Raymond, M., and Turcotte, B. 2005. Candida albicans zinc cluster protein Upc2p confers resistance to antifungal drugs and is an activator of ergosterol biosynthetic genes. Antimicrob. Agents Chemother.49, 1745–1752.
40. Mansfield, B.E., Oltean, H.N., Oliver, B.G., Hoot, S.J., Leyde, S.E., Hedstrom, L., and White, T.C. 2010. Azole drugs are imported by facilitated diffusion in Candida albicans and other pathogenic fungi. PLoS Pathog.6, e1001126.
41. Marr, K.A., Lyons, C.N., Ha, K., Rustad, T.R., and White, T.C. 2001. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob. Agents Chemother.45, 52–59.
42. Marr, K.A., Lyons, C.N., Rustad, T.R., Bowden, R.A., and White, T.C. 1998. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob. Agents Chemother.42, 2584–2589.
43. Martel, C.M., Parker, J.E., Bader, O., Weig, M., Gross, U., Warrilow, A.G., Rolley, N., Kelly, D.E., and Kelly, S.L. 2010. Identification and characterization of four azole-resistant erg3 mutants of Candida albicans. Antimicrob. Agents Chemother.54, 4527–4533.
44. Martinez, M., Lopez-Ribot, J.L., Kirkpatrick, W.R., Bachmann, S.P., Perea, S., Ruesga, M.T., and Patterson, T.F. 2002. Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis. J. Antimicrob. Chemother.49, 515–524.
45. Miller, M.G. and Johnson, A.D. 2002. White-opaque switching in Candida albicans is controlled by mating-type locus homeodomain proteins and allows efficient mating. Cell110, 293–302.
46. Miyazaki, T., Miyazaki, Y., Izumikawa, K., Kakeya, H., Miyakoshi, S., Bennett, J.E., and Kohno, S. 2006. Fluconazole treatment is effective against a Candida albicans erg3/erg3 mutant in vivo despite in vitro resistance. Antimicrob. Agents Chemother.50, 580–586.
47. Miyazaki, Y., Geber, A., Miyazaki, H., Falconer, D., Parkinson, T., Hitchcock, C., Grimberg, B., Nyswaner, K., and Bennett, J.E. 1999. Cloning, sequencing, expression and allelic sequence diversity of ERG3 (C-5 sterol desaturase gene) in Candida albicans. Gene236, 43–51.
48. 5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence. J. Antimicrob. Chemother.67, 2131–2138.
49. Morschhäuser, J., Barker, K.S., Liu, T.T., Blaβ- Warmuth, J., Homayouni, R., and Rogers, P.D. 2007. The transcription factor Mrr1p controls expression of the MDR1 efflux pump and mediates multidrug resistance in Candida albicans. PLoS Pathog.3, e164.
50. Morschhäuser, J., Michel, S., and Staib, P. 1999. Sequential gene disruption in Candida albicans by FLP-mediated site-specific recombination. Mol. Microbiol.32, 547–556.
51. Perea, S., Lopez-Ribot, J.L., Kirkpatrick, W.R., McAtee, R.K., Santillan, R.A., Martinez, M., Calabrese, D., Sanglard, D., and Patterson, T.F. 2001. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother.45, 2676–2684.
52. Ramírez-Zavala, B., Reuβ, O., Park, Y.N., Ohlsen, K., and Morschhäuser, J. 2008. Environmental induction of white-opaque switching in Candida albicans. PLoS Pathog.4, e1000089.
53. Rustad, T.R., Stevens, D.A., Pfaller, M.A., and White, T.C. 2002. Homozygosity at the Candida albicans MTL locus associated with azole resistance. Microbiology148, 1061–1072.
54. Saidane, S., Weber, S., De Deken, X., St-Germain, G., and Raymond, M. 2006. PDR16-mediated azole resistance in Candida albicans. Mol. Microbiol.60, 1546–1562.
55. Sanglard, D., Ischer, F., Koymans, L., and Bille, J. 1998. Amino acid substitutions in the cytochrome P-450 lanosterol 14a-demethylase (CYP51A1) from azole-resistant Candida albicans clinical isolates contribute to resistance to azole antifungal agents. Antimicrob. Agents Chemother.42, 241–253.
56. Sanglard, D., Ischer, F., Marchetti, O., Entenza, J., and Bille, J. 2003a. Calcineurin A of Candida albicans: involvement in antifungal tolerance, cell morphogenesis and virulence. Mol. Microbiol.48, 959–976.
57. Sanglard, D., Ischer, F., Monod, M., and Bille, J. 1996. Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors. Antimicrob. Agents Chemother.40, 2300–2305.
58. Sanglard, D., Ischer, F., Monod, M., and Bille, J. 1997. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology143, 405–416.
59. Sanglard, D., Ischer, F., Parkinson, T., Falconer, D., and Bille, J. 2003b. Candida albicans mutations in the ergosterol biosynthetic pathway and resistance to several antifungal agents. Antimicrob. Agents Chemother.47, 2404–2412.
60. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J.L., Monod, M., and Bille, J. 1995. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob. Agents Chemother.39, 2378–2386.
61. Sasse, C., Dunkel, N., Schäfer, T., Schneider, S., Dierolf, F., Ohlsen, K., and Morschhäuser, J. 2012. The stepwise acquisition of fluconazole resistance mutations causes a gradual loss of fitness in Candida albicans. Mol. Microbiol.86, 539–556.
62. Schillig, R. and Morschhäuser, J. 2013. Analysis of a fungus-specific transcription factor family, the Candida albicans zinc cluster proteins, by artificial activation. Mol. Microbiol.89, 1003–1017.
63. Schubert, S., Barker, K.S., Znaidi, S., Schneider, S., Dierolf, F., Dunkel, N., Aid, M., Boucher, G., Rogers, P.D., Raymond, M., et al. 2011. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in Candida albicans. Antimicrob. Agents Chemother.55, 2212–2223.
64. Schubert, S., Rogers, P.D., and Morschhäuser, J. 2008. Gain-offunction mutations in the transcription factor MRR1 are responsible for overexpression of the MDR1 efflux pump in fluconazole- resistant Candida dubliniensis strains. Antimicrob. Agents Chemother.52, 4274–4280.
65. Schulz, B., Weber, K., Schmidt, A., Borg-von Zepelin, M., and Ruhnke, M. 2011. Difference in virulence between fluconazole- susceptible and fluconazole-resistant Candida albicans in a mouse model. Mycoses54, e522530.
66. Selmecki, A., Forche, A., and Berman, J. 2006. Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science313, 367–370.
67. Selmecki, A., Gerami-Nejad, M., Paulson, C., Forche, A., and Berman, J. 2008. An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol. Microbiol.68, 624–641.
68. Selmecki, A.M., Dulmage, K., Cowen, L.E., Anderson, J.B., and Berman, J. 2009. Acquisition of aneuploidy provides increased fitness during the evolution of antifungal drug resistance. PLoS Genet.5, e1000705.
69. Silver, P.M., Oliver, B.G., and White, T.C. 2004. Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot. Cell3, 1391–1397.
70. Talibi, D. and Raymond, M. 1999. Isolation of a putative Candida albicans transcriptional regulator involved in pleiotropic drug resistance by functional complementation of a pdr1 pdr3 mutation in Saccharomyces cerevisiae. J. Bacteriol.181, 231–240.
71. Tsao, S., Rahkhoodaee, F., and Raymond, M. 2009. Relative contributions of the Candida albicans ABC transporters Cdr1p and Cdr2p to clinical azole resistance. Antimicrob. Agents Chemother.53, 1344–1352.
72. 5,6-desaturase gene (ERG3) in Candida albicans does not necessarily decrease virulence. Antimicrob. Agents Chemother.56, 1960–1968.
73. Wang, Y., Liu, J.Y., Shi, C., Li, W.J., Zhao, Y., Yan, L., and Xiang, M.J. 2015. Mutations in transcription factor Mrr2p contribute to fluconazole resistance in clinical isolates of Candida albicans. Int. J. Antimicrob. Agents46, 552–559.
74. White, T.C. 1997a. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother.41, 1482–1487.
75. White, T.C. 1997b. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14a demethylase in Candida albicans. Antimicrob. Agents Chemother.41, 1488–1494.
76. White, T.C., Marr, K.A., and Bowden, R.A. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev.11, 382–402.
77. Wirsching, S., Michel, S., and Morschhäuser, J. 2000. Targeted gene disruption in Candida albicans wild-type strains: the role of the MDR1 gene in fluconazole resistance of clinical Candida albicans isolates. Mol. Microbiol.36, 856–865.
78. Znaidi, S., De Deken, X., Weber, S., Rigby, T., Nantel, A., and Raymond, M. 2007. The zinc cluster transcription factor Tac1p regulates PDR16 expression in Candida albicans. Mol. Microbiol.66, 440–452.
79. Znaidi, S., Weber, S., Al-Abdin, O.Z., Bomme, P., Saidane, S., Drouin, S., Lemieux, S., De Deken, X., Robert, F., and Raymond, M. 2008. Genomewide location analysis of Candida albicans Upc2p, a regulator of sterol metabolism and azole drug resistance. Eukaryot. Cell7, 836–847.